AU2006347740A1 - Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases - Google Patents

Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases Download PDF

Info

Publication number
AU2006347740A1
AU2006347740A1 AU2006347740A AU2006347740A AU2006347740A1 AU 2006347740 A1 AU2006347740 A1 AU 2006347740A1 AU 2006347740 A AU2006347740 A AU 2006347740A AU 2006347740 A AU2006347740 A AU 2006347740A AU 2006347740 A1 AU2006347740 A1 AU 2006347740A1
Authority
AU
Australia
Prior art keywords
composition
colchicine
nab
individual
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006347740A
Other languages
English (en)
Inventor
Neil P. Desai
Vuong Trieu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC
Publication of AU2006347740A1 publication Critical patent/AU2006347740A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2006347740A 2006-08-31 2006-08-31 Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases Abandoned AU2006347740A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/034365 WO2008027055A1 (en) 2006-08-31 2006-08-31 Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases

Publications (1)

Publication Number Publication Date
AU2006347740A1 true AU2006347740A1 (en) 2008-03-06

Family

ID=37763804

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006347740A Abandoned AU2006347740A1 (en) 2006-08-31 2006-08-31 Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases

Country Status (9)

Country Link
EP (1) EP2056812A1 (es)
JP (1) JP2010502603A (es)
CN (1) CN101568332A (es)
AU (1) AU2006347740A1 (es)
BR (1) BRPI0622006A2 (es)
CA (1) CA2662140A1 (es)
IL (1) IL197276A0 (es)
MX (1) MX2009002054A (es)
WO (1) WO2008027055A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUE048521T2 (hu) 2005-08-31 2020-08-28 Abraxis Bioscience Llc Gyengén vízoldékony gyógyszerészeti és antimikrobális hatóanyagokat tartalmazó keverékek
PT2117520T (pt) 2006-12-14 2018-12-04 Abraxis Bioscience Llc Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane
PT2481409T (pt) 2007-03-07 2018-10-18 Abraxis Bioscience Llc Nanopartícula que compreende rapamicina e albumina como agente anticancerígeno
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
TW201012473A (en) * 2008-09-22 2010-04-01 Tty Biopharm Co Ltd Composition of inhibiting pathological angiogenesis
US20100297243A1 (en) 2009-04-15 2010-11-25 Desai Neil P Prion free nanoparticle compositions and methods of making thereof
WO2011076095A1 (en) * 2009-12-21 2011-06-30 Tty Biopharm Company Limited Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
LT2552438T (lt) 2010-03-26 2016-09-26 Abraxis Bioscience, Llc Hepatoceliulinės karcinomos gydymo būdai
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
LT2552415T (lt) 2010-03-29 2016-12-27 Abraxis Bioscience, Llc Vėžio gydymo būdai
RU2576609C2 (ru) 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечение рака поджелудочной железы
US20140228299A1 (en) * 2011-09-20 2014-08-14 National University Corporation Tokyo Medical And Dental University Prophylactic and therapeutic agent for neurological diseases using lipoproteins and prophylactic and therapeutic method for neurological diseases
SI2790675T1 (sl) 2011-12-14 2019-11-29 Abraxis Bioscience Llc Uporaba polimernih pomožnih snovi za liofilizacijo ali zamrzovanje delcev
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CN105228612A (zh) 2013-03-12 2016-01-06 阿布拉科斯生物科学有限公司 治疗肺癌的方法
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
EP2924022A1 (en) * 2014-03-27 2015-09-30 INDENA S.p.A. Amorphous form of a thiocolchicine derivative
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
EA202092187A1 (ru) 2015-06-29 2021-08-31 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения эпителиоидно-клеточных опухолей
JP2021528362A (ja) 2018-03-20 2021-10-21 アブラクシス バイオサイエンス， エルエルシー ｍＴＯＲ阻害剤およびアルブミンのナノ粒子の投与を介して中枢神経系障害を処置する方法
CN115003284A (zh) 2019-10-28 2022-09-02 阿布拉科斯生物科学有限公司 白蛋白和雷帕霉素的药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318401B1 (it) * 2000-03-17 2003-08-25 Indena Spa Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono.
SI1585548T1 (sl) * 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
PT1585548T (pt) * 2002-12-09 2018-10-17 Abraxis Bioscience Llc Composições e métodos de administração de agentes farmacológicos
US6825236B2 (en) * 2003-04-14 2004-11-30 California Pacific Medical Center Colchicine derivatives
ITMI20040164A1 (it) * 2004-02-03 2004-05-03 Indena Spa Derivati di n.deacetiltiocolchicina loro uso e formulazioni farmaceutiche che li contengono
SI3248600T1 (sl) * 2005-02-18 2020-09-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija

Also Published As

Publication number Publication date
WO2008027055A1 (en) 2008-03-06
JP2010502603A (ja) 2010-01-28
IL197276A0 (en) 2009-12-24
EP2056812A1 (en) 2009-05-13
CA2662140A1 (en) 2008-03-06
CN101568332A (zh) 2009-10-28
MX2009002054A (es) 2009-05-01
BRPI0622006A2 (pt) 2011-12-20

Similar Documents

Publication Publication Date Title
US20080280987A1 (en) Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
AU2006347740A1 (en) Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
AU2019202037B2 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
CA2598239C (en) Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
CA2680207C (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
RU2561055C2 (ru) Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог
DK2117520T3 (en) BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN
ES2243744T3 (es) Inhibidores de integrina para el tratamiento de enfermedades de los ojos.
PT2481405E (pt) Nanopartículas de paclitaxel e albumina em combinação com bevacizumab contra o cancro
US20230277454A1 (en) NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER
JP2021521173A (ja) 眼内薬物送達用の持続放出微粒子のための方法及び組成物
ES2315312T3 (es) Procedimiento y composiciones para el tratamiento de enfermedades del ojo.
US20180185321A1 (en) Talc-bound compositions and uses thereof
Zhai et al. Nanomedicines for the treatment of glaucoma: current status and future perspectives
KR101644440B1 (ko) 개선된 혈관신생 억제용 펩티드와 이를 유효성분으로 함유하는 혈관신생과 관련된 질환의 예방 및 치료용 조성물
KR20090057074A (ko) 혈관형성 억제 및 혈관형성 관련 질환 치료 방법
TW200810745A (en) Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
AU2013204181A1 (en) Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
US20190275001A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
CA2917298C (en) Novel formulations of factor viia inhibitors and utility
Berillo et al. Review of Recent Advances in the Use of Drug Delivery Systems in Ophthalmology
KR20220122647A (ko) 망막모세포종의 치료를 위한 약제학적 조성물, 제형 및 방법

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application